Tracer library / [177Lu]Lu-DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2

[177Lu]Lu-DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2

Also written as [Lu-177]Lu-DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2; Lu-177-DOTA-(d-Glu)6-Ala-Tyr-Gly-Trp-Nle-Asp-PheNH2; Lu-177-DOTA-(dGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2
Radionuclide
Lu-177 t½ 9584.6 min
Modality
Therapy
Production route
—
Stage
—
Syntheses indexed
1
Preclinical only, no clinical indication yet

What it is

Compound class
DOTA-conjugated minigastrin (gastrin) analogue peptide
Target / mechanism
CCKBR (cholecystokinin B receptor)-targeting radiolabeled minigastrin analogue PMID 34959437
Clinical application
CCKBR-positive cancers PMID 34959437
Theranostic pair
—

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesis
Merck Hitachi
—HPLC—>99%PP-F11N…PP-F11N (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe)
PSL GmbH, Heidelberg, Germany
34959437
2021 Pharmaceutics
the purification of [177Lu]Lu-PP-F11N was accomplished by using a Merck Hitachi LaChrom 2D HPLC system as previously described

Precursor

Common precursor
—
Suppliers seen in the literature
—
Cited suppliers in indexed syntheses
PSL GmbH
Typical final purification
—

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 34959437: 'The N-terminal DOTA-conjugated gastrin analogue PP-F11N (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe)'.
Ask a question